Fig. S2 NMR analysis of CP-2 antiamyloidogenic activity. (a)
1 H spectrum of AcPHF6 with assignments obtained from combination of TOCSY and NOESY spectra. NMR measurements were conducted on a sample of AcPHF6 (100 µM) in 50 mM d3-NaAc buffer in 95% 2 H2O/5% signals is indicative of a reduction in soluble (monomeric) AcPHF6, which is much more pronounced in the absence of CP-2 (~55%) as opposed to samples containing the peptide (~30%). All measurements were performed on a DRX700 Bruker spectrometer using a cryogenic triple-resonance TCI probehead equipped with z-axis pulsed field gradients. 
Materials and Methods
All chemicals and reagents were of analytical grade. 2-Chlorotrityl-chloride, 9-fluorenylmethoxycarbonyl (Fmoc)-protected amino acid derivatives, and all other reagents for solid-phase peptide synthesis were purchased from Shanghai Hanhong Scientific (Shanghai, China) and used as received. Unless otherwise stated, all other chemicals were obtained from Sigma-Aldrich (Rehovot, Israel). Peptide analogs were synthesized using solid-phase peptide synthesis, employing the common Fmoc strategy. 1 Cyclic D,L-α-peptides were synthesized on 2-chlorotrityl chloride resin, as described. Synthesis of NBD-conjugated PHF6. PHF6 was synthesized on Rink amide resin as described.
Following the assembly of the peptide on the resin, the N-terminus of the peptide was conjugated to NBD, using NBD-Cl and DIPEA (2:2 eq.) in DMF for 16 h. The peptide was then 
